We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Idenix Sues to Keep Gilead’s Hep C Drug Off of the Market
Idenix Sues to Keep Gilead’s Hep C Drug Off of the Market
Following setbacks to its hepatitis C drug program, Idenix Pharmaceuticals is appealing to the courts to keep Gilead’s competing hepatitis C treatment off pharmacy shelves.